Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth S Lowe

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.
The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Gynecologic Oncology|November 13, 2024
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancerKatherine Elizabeth Francis, Sandy Simon, Val Gebski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer: Phase III SOLO3 Study Final Overall Survival ResultsGiovanni Scambia, Ricardo Villalobos Valencia, Nicoletta Colombo, et al.
The Lancet. Oncology|October 29, 2021
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trialSusana Banerjee, Kathleen N Moore, Nicoletta Colombo, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
The Lancet. Oncology|July 30, 2017
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialEric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, et al.
Gynecologic Oncology|August 6, 2021
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trialNicoletta Colombo, Kathleen Moore, Giovanni Scambia, et al.
The New England Journal of Medicine|October 23, 2018
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian CancerKathleen Moore, Nicoletta Colombo, Giovanni Scambia, et al.
British Journal of Cancer|October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapyMichael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
Gynecologic Oncology|February 4, 2022
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 studyFabian Trillsch, Sven Mahner, Beyhan Ataseven, et al.
Lancet (London, England)|November 26, 2008
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S Kim, Vera Hirsh, Tony Mok, et al.
Pageof 3